Press Releases Year None202320222021202020192018 May 31, 2023 Akero Therapeutics to Present at the Jefferies Healthcare Conference May 16, 2023 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock May 15, 2023 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Mar 29, 2023 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH Mar 17, 2023 Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Jan 10, 2023 Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy Jan 04, 2023 Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Year None202320222021202020192018 May 31, 2023 Akero Therapeutics to Present at the Jefferies Healthcare Conference May 16, 2023 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock May 15, 2023 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Mar 29, 2023 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH Mar 17, 2023 Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Jan 10, 2023 Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy Jan 04, 2023 Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
May 16, 2023 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
May 15, 2023 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Mar 29, 2023 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
